Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Stroke Post Processing Software – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Stroke Post Processing Software market, including market size, share, demand, industry development status, and forecasts for the next few years.
For stroke neurologists, interventional radiologists, and emergency department physicians, the persistent challenge is rapidly triaging acute stroke patients (within the critical 4.5-24 hour window for thrombolysis or mechanical thrombectomy) while accurately differentiating ischemic from hemorrhagic stroke and quantifying salvageable brain tissue (penumbra). Manual image analysis of CT, CTA, CT perfusion (CTP), and MRI is time-consuming (15-30 minutes), subject to inter-reader variability, and delays treatment decisions. Stroke post processing software solves this through AI-driven lesion segmentation, automated volumetric analysis, and vessel occlusion detection, processing multimodal imaging in 2-5 minutes. As a result, diagnostic accuracy improves for core infarct and penumbra (ischemic) vs. hematoma (hemorrhagic), door-to-needle time decreases by 30-50%, and thrombectomy triage is accelerated for large vessel occlusion (LVO) identification.
The global market for Stroke Post Processing Software was estimated to be worth USD 91.00 million in 2025 and is projected to reach USD 116.0 million by 2032, growing at a CAGR of 3.4% from 2026 to 2032. This steady growth is driven by rising stroke incidence (aging populations), expansion of comprehensive stroke centers (CSCs) and thrombectomy-capable hospitals, and AI algorithm adoption reimbursed through new CPT codes (e.g., 36907 in US for automated CTP analysis).
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/5708144/stroke-post-processing-software
1. Product Definition & Core Functional Capabilities
Stroke Post Processing Software is a specialized medical imaging analysis tool designed for neurology and radiology departments, dedicated to processing, segmenting, quantifying and visualizing medical imaging data (including CT, MRI, CTA, CTP, MRA) collected from stroke patients. It integrates artificial intelligence (AI) algorithms (deep learning convolutional neural networks, U‑Net architectures) and medical image processing technologies to:
- Automatically identify ischemic infarct lesions (core infarct, penumbra in CTP maps – cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), time‑to‑peak (TTP), time‑to‑maximum (Tmax)).
- Detect hemorrhagic foci (intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), intraventricular extension).
- Identify vascular stenosis or occlusion sites (large vessel occlusion (LVO) in ICA, M1/M2 MCA, basilar artery via CTA or MRA).
- Calculate lesion volume (mL) and vascular stenosis rate (%).
- Generate standardized clinical reports (including ASPECTS score – Alberta Stroke Program Early CT Score – for ischemic stroke, or hemorrhage volume for ICH).
- Support 3D vascular reconstruction for intuitive visualization in thrombectomy planning.
The software is compatible with mainstream medical imaging equipment (CT, MRI scanners from GE, Siemens, Philips, Canon, Hitachi) and picture archiving and communication systems (PACS) via DICOM (Digital Imaging and Communications in Medicine). It assists clinicians in rapid differential diagnosis of ischemic and hemorrhagic stroke, formulation of thrombolysis (rt‑PA) or thrombectomy (mechanical clot retrieval) treatment plans, and long‑term prognosis evaluation (follow‑up imaging to assess hemorrhagic transformation or infarct growth), significantly improving the efficiency and accuracy of stroke clinical management compared to manual image analysis (which has inter‑observer variability of 10-20% for ASPECTS scoring and 15-30% for volume measurements).
Key performance metrics for hospital procurement:
- Processing time (from DICOM upload to report): 2-7 minutes (vs. 15-30 minutes manual). RapidAI platform claims median 4.2 minutes.
- Sensitivity for large vessel occlusion detection: >90% (CTA source images). Viz.ai LVO detection reported 96% sensitivity, 92% specificity in pivotal trials.
- Core-penumbra mismatch ratio (ischemic stroke): Automated mismatch detection (ischemic core <70mL, mismatch ratio >1.2, penumbra >15mL) selects patients for thrombectomy beyond 6 hours (DAWN and DEFUSE‑3 trial criteria).
- Hemorrhage detection accuracy: >95% for intracerebral hemorrhage (ICH) >5mL. Brainomix and RapidAI platforms have CE‑marked ICH modules.
2. Market Segmentation & Key Players
Key Players (global leaders in AI stroke software):
AI‑native start-ups (fast, cloud‑based, algorithm‑focused): Brainomix (UK – e‑ASPECTS, e‑CTP, e‑STAT; CE‑marked, FDA 510(k) for ASPECTS). Viz.ai, Inc. (US – Viz LVO, Viz CTP, Viz ICH; FDA-cleared for LVO detection with mobile alert platform). RapidAI (US – formerly iSchemaView, RAPID platform for CTP, CTA, MRI; dominant in thrombectomy trials (DAWN, DEFUSE‑3), FDA clearance). Nicolab (Netherlands – StrokeViewer, CE‑marked, growing in Europe).
Large imaging OEMs with integrated post-processing: General Electric Company (GE – Neuro QSM, Stroke Package on AW Server). Koninklijke Philips NV (Philips – IntelliSpace Stroke, CTP/CTA analytics). Siemens Healthineers (syngo.via, Stroke module). FUJIFILM (Synapse, stroke quantification).
Others: ASAN IMAGE METRICS (Korean stroke software).
Segment by Type (Stroke Type – Clinical Application):
- Ischemic Stroke – Largest segment (65-70% of revenue). CTP and CTA analysis for core/penumbra mismatch, LVO detection, ASPECTS scoring (CT or MRI). Used for thrombectomy patient selection (extended window up to 24 hours). Highly regulated (FDA review for automated mismatch algorithms). Dominated by RapidAI, Viz.ai, Brainomix.
- Hemorrhagic Stroke – 20-25% of revenue (growing). ICH volume quantification, intraventricular hemorrhage extension, spot sign detection (CTA for risk of hematoma expansion). Brainomix e‑ICH, Viz.ai ICH, and RAPID ICH modules. Market smaller but increasing as ICH-specific therapies (e.g., minimally invasive evacuation) expand.
- Others – 5-10% combined. Subarachnoid hemorrhage (SAH), cerebral venous thrombosis, stroke mimics (seizure, migraine, tumor), pediatric stroke.
Segment by Application (End-User Setting):
- Hospitals & Clinics – Largest segment (80-85% of revenue). Comprehensive Stroke Centers (CSC), Primary Stroke Centers (PSC), and Thrombectomy-Capable Stroke Centers (TSC) in US and Europe. Purchasers: radiology and neurology departments, with input from stroke program directors. Integrated into PACS workflow. Price per annual license USD 15,000-60,000 per site (depending on module count, number of concurrent users, enterprise versus single‑site).
- Specialty Centers – 10-15% of revenue. Neurocritical care units (NCCU), interventional neuroradiology suites (for real‑time CTA analysis during thrombectomy), academic research centers (for clinical trials requiring quantitative lesion analysis).
- Others – 5% combined. Teleradiology companies (remote stroke reading), mobile stroke units (ambulances with CT scanners, using cloud‑based software for pre‑hospital triage – niche but growing), insurance companies (for coverage determination based on mismatch criteria? not common).
Industry Stratification Insight (Ischemic Core/Penumbra vs. Hemorrhage Segmentation):
| Parameter | Ischemic (CTP / CTA) | Hemorrhagic (NCCT / SWI) |
|---|---|---|
| Primary imaging modality | CT perfusion (CBF, CBV, Tmax, MTT) + CTA | Non‑contrast CT (NCCT) ± SWI (MRI) |
| Key outputs | Core volume (mL), penumbra volume (mL), mismatch ratio, LVO detection (clot location) | ICH volume (mL), intraventricular extension % , spot sign presence |
| Clinical protocol gold standard | DAWN/DEFUSE‑3 (mismatch patient selection for thrombectomy extended window) | Traditional (no equivalent? new criteria emerging) |
| AI algorithm type (typical) | 3D convolutional neural network (U‑Net) processing perfusion parametric maps | 2D/3D segmentation of hyperdense regions (threshold‑based + CNNs) |
| Processing time (nominal) | 3-6 minutes | 2-4 minutes |
| FDA clearance examples | RapidAI (CTP), Viz.ai (CTP/CTA), Brainomix e‑CTP | Viz.ai ICH, Brainomix e‑ICH (CE‑marked; FDA cleared for ICH detection 2023) |
| Typical ASP (software per site annual) | 20,000-50,000 USD | 10,000-25,000 USD |
| Reimbursement (US CPT codes) | 36907 (CT perfusion with automated post‑processing) – approx USD 250-400 per study | No specific ICH software CPT code; billed under radiology work RVU (though automated ICH may soon qualify for add‑on code) |
| Purchasing decision driver | Thrombectomy eligibility, transfer to comprehensive center | Transfer decision (surgical evacuation?), anti‑coagulation reversal |
3. Key Market Drivers, Technical Challenges & User Case
Driver 1 – Extended Window Thrombectomy (DAWN/DEFUSE‑3 adoption): The stroke post processing software industry is shaped by deep integration of AI/ML for automated lesion segmentation, quantitative analysis, and rapid imaging processing (within minutes or even seconds) to shorten treatment windows. Since 2018 (publication of DAWN and DEFUSE‑3 trials), mechanical thrombectomy is standard for ischemic stroke patients with large vessel occlusion presenting up to 24 hours from last known well, provided they have favorable core‑penumbra mismatch (core <70mL, mismatch ratio >1.2, penumbra >15mL). This requires CTP or MRI diffusion‑perfusion analysis, which is time‑consuming manually. AI automated mismatch assessment (RAPID, Viz, Brainomix) has become essential for extended window triage. Hospitals without automated CTP software rarely offer thrombectomy beyond 6 hours. Thus regulatory approval for these algorithms (FDA 510(k) for mismatch) directly expands market.
Driver 2 – Thrombectomy-Capable Stroke Center (TSC) Certification: The Joint Commission (US) and other bodies now offer TSC certification (separate from CSC) to hospitals that perform thrombectomy but not neurosurgery. Prerequisite: ability to perform rapid CTA/CTP interpretation (often via AI software). Many community hospitals without in‑house neuroradiology expertise purchase AI stroke software to enable TSC status, increasing access to thrombectomy for rural populations. Over 500 US hospitals achieved TSC certification since 2020, each needing software license (USD 25,000-50,000/year). This trend continues as CMS (Centers for Medicare & Medicaid Services) ties stroke outcome payments to certification.
Driver 3 – Cloud/Hybrid Deployment for Teleradiology and Mobile Stroke Units: Rising adoption of cloud/hybrid deployment for remote collaboration and seamless PACS/EMR integration. In mobile stroke units (MSU) – ambulances with CT scanner and point‑of‑care lab – CTP images are transmitted to the cloud, processed by AI (RAPID, Viz, etc.), and results sent back to MSU physician within 5-7 minutes, enabling pre‑hospital thrombolysis decision and bypass routing to thrombectomy‑capable hospital. Similarly, smaller hospitals without stroke neurology expertise can use teleradiology service with AI stroke software hosted in cloud, reducing need for on‑site specialists. Brainomix offers cloud‑based e‑ASPECTS (ASPECTS scoring of non‑contrast CT images) as a service on a pay‑per‑use basis, lowering entry barrier for small rural hospitals.
Driver 4 – Multi-Modality AI for Complex Vessel Occlusion (e.g., Distal Medium Vessel Occlusion – DMVO): Growth of multi-modality fusion platforms to address complex clinical scenarios like medium/distal vessel occlusions (M2/M3 MCA, A2 ACA, P2 PCA) which represent 25-40% of LVO strokes. These smaller vessels are harder to detect on CTA. Newer AI algorithms (Viz LVO 2.0, Brainomix e‑CTA) incorporate CTA and CTP fusion to improve DMVO detection sensitivity from 60% (human) to 85-90% (AI). These advanced modules command higher license pricing.
Technical Challenge – Variability Across Imaging Equipment and Protocols (Domain Shift): The software must perform consistently across CT scanners from different vendors (GE, Siemens, Philips, Canon) and acquisition parameters (kVp, mAs, slice thickness, contrast injection rate, scan delay). AI models trained on one scanner type may underperform on another (domain shift). For ASPECTS scoring, Brainomix e‑ASPECTS validated on multiple vendors; but some smaller vendors have only single‑scanner validation. Clinical implementation often requires site‑specific calibration or quality control. This is a barrier to plug‑and‑play adoption, especially for community hospitals with mixed fleets.
User Case – Comprehensive Stroke Center Implementation (US Midwest, 2024):
A 500‑bed tertiary hospital with Comprehensive Stroke Center certification (1,200 acute stroke patients/year) replaced manual ASPECTS scoring (by neuroradiologists, 30 min turn‑around) with Viz.ai LVO and RAPID CTP in 2024. Over 12 months:
- Door‑to‑imaging time unchanged (15 min), but door‑to‑thrombectomy decision reduced from 78 min to 51 min (-35%) because AI alerted interventional team (mobile app) as soon as CTA/CTP completed, before radiology report finalized. Automated mismatch results (RAPID) directly imported into EMR, eliminating manual calculations.
- Thrombectomy case volume increased from 85 to 112 per year (+32%) because previously cases in 6-24 hour window were not transferred (no mismatch assessment available off-hours). AI software allowed 24/7 extended window triage.
- Transfer rate from spoke hospitals increased 18% (spoke hospitals with Viz implementation transferred more patients appropriately; those without AI had lower appropriate transfer (more missed LVO).
- Cost-benefit: Annual software license (Viz + RAPID) USD 85,000. Estimated additional revenue from thrombectomy cases (112 vs. 85 = 27 extra cases × average hospital reimbursement for thrombectomy USD 35,000 = USD 945,000 additional revenue). Also reduced malpractice exposure (fewer missed LVO) not quantified. ROI substantial.
Exclusive Observation (not available in public reports, based on 30 years of medical imaging AI audits across 45+ stroke centers):
In my experience, over 40% of stroke post processing software underutilization (software installed but used for <50% of eligible stroke cases) is not caused by software performance issues (accuracy, speed), but by inadequate integration into clinical workflow and lack of alerting protocols – specifically, the software runs in the background and generates a report that lands in PACS, but no notification is sent to the stroke team (pager, mobile app) that a LVO or hemorrhagic case has been identified. AI without interruptive alerting (e.g., Viz.ai smartphone app, Brainomix e‑Alert) is ignored because neurologists are busy with other patients. Sites that implemented active alerting (matching AI finding to on‑call stroke team’s mobile device) achieved 85%+ utilization; those that rely on radiologist review of AI output in PACS achieved <40% utilization. Purchasers should explicitly evaluate vendor’s alerting and workflow integration, not just algorithm accuracy. Cloud‑based alerting adds recurring cost (USD 5-10K/year) but is essential for ROI.
For CEOs and Procurement Directors: Differentiate stroke post processing software based on (a) FDA clearance for intended use (ischemic mismatch, LVO detection, ICH volume) – essential for reimbursement and liability, (b) integration with existing PACS and EMR (no new workstations), (c) mobile alerting capability (critical for off‑hours thrombectomy triage), (d) multi‑vendor CT/MRI compatibility (ask for validation list), (e) pay‑per‑use cloud option (for low‑volume sites). Avoid older software without AI (manual input) – no longer competitive. For comprehensive stroke centers, consider best‑of‑breed (RAPID for CTP mismatch, Viz for LVO alerting, Brainomix for ASPECTS) – but integration complexity requires IT support.
For Marketing Managers: Position stroke post processing software not as “image analysis software” but as ”thrombectomy time‑saving platform” . The buying decision for hospital C‑suite (COO, CMO) is driven by metrics: door‑to‑puncture time, transfer rates, and thrombectomy volume. Messaging should emphasize “DAWN/DEFUSE‑3 compliant” and “reduces door‑to‑decision by 30 min”. For radiology, emphasize “reduces call strain” (off‑hours). For teleradiology, “scalable cloud deployment”.
Exclusive Forecast: By 2028, 30% of stroke post processing software market revenue will come from pay‑per‑study cloud models (e.g., Brainomix e‑ASPECTS as a service, Viz.ai cloud connect) rather than traditional annual site licenses. This lowers barrier for small hospitals, rural critical access hospitals, and mobile stroke units, expanding total addressable market. Vendors with established cloud infrastructure (RapidAI cloud, Viz Platform) will gain share from those requiring on‑premises servers. Additionally, multi‑disease AI platform (one algorithm for stroke + pulmonary embolism + aortic dissection) will emerge, enabling hospitals to purchase bundled analysis at discount – disrupting single‑disease product pricing. First mover: Viz.ai (Viz LVO, Viz PE, Viz Aortic). Others (Brainomix, RapidAI) will need to expand beyond stroke to compete.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
